Today March 28 the Swedish market close at 13.00. Danish and Norweigan markets is closed.

Dicot is developing the drug candidate LIB-01, which is expected to be a potency drug to treat erectile dysfunction and premature ejaculation. Duration of action and fewer side effects are main desired properties. Dicot's main strategy is to develop LIB-01 in-house up to and including clinical phase 2a study, and then in partnership with major pharmaceutical companies to finance and further develop LIB-01 into a registered drug for the world market.

Quotes for Dicot AB

Right Now

+/-
0.0015
%
0,75%
Latest
0.201
High
0.205
Low
0.195
Volume
1 314 782
Turnover (SEK)
266 311
Market Value (MSEK)
164,3
Time (Latest trade)
2024-03-28 12:59

Board

CEO

  • Elin Trampe

Chairperson of the Board

  • Eva Sjökvist

Board

  • Fredrik Buch
  • Jan-Eric Österlund
  • Michael Zell
  • Mikael von Euler
  • Per-Göran Gillberg

Videos

Largest Owners

Name Capital % Votes % Date
Avanza Pension 11,01 11,01 2023-12-27
Bertil Lindkvist 8,26 8,26 2023-12-27
Tore Robertsson 3,42 3,42 2023-12-27
Nordnet Pensionsförsäkring 2,65 2,65 2023-12-27
Torsten Söderberg med familj 1,98 1,98 2023-12-27
Kenneth Sjökvist 1,21 1,21 2023-12-27
Klas Göran Viktor Strömberg 1,10 1,10 2023-12-27
Michael Zell 1,00 1,00 2023-12-27
Gunilla Paalberg 0,81 0,81 2023-12-27
Johan Thorell 0,78 0,78 2023-12-27
** Holdings by Modular Finance AB. Compiled and processed data from various sources, including Euroclear, Morningstar and the Swedish Financial Supervisory Authority.

Insider trading

Key Numbers

*Compiled data from Millistream